Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone versus olanzapine for schizophrenia.

M B Jayaram1, P Hosalli

  • 1Becklin Centre, St James University Hospital, Leeds, West Yorkshire, UK, LS9 3BE. maheshbj@hotmail.com

The Cochrane Database of Systematic Reviews
|April 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing long acting antipsychotic injection dosage frequency: A pilot study in a community mental health team.

Journal of mental health (Abingdon, England)·2020
Same author

Risperidone versus olanzapine for schizophrenia.

The Cochrane database of systematic reviews·2006
Same author

Depot risperidone for schizophrenia.

The Cochrane database of systematic reviews·2003
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Risperidone and olanzapine show similar short-term efficacy for schizophrenia treatment. However, olanzapine may reduce relapse risk, while risperidone is linked to more movement disorders and sexual dysfunction, and olanzapine to significant weight gain.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Risperidone and olanzapine are popular second-generation antipsychotics for schizophrenia.
  • These medications are frequently prescribed as first-line treatments.

Purpose of the Study:

  • To compare the clinical effects, safety, and cost-effectiveness of risperidone versus olanzapine in schizophrenia treatment.
  • To evaluate the comparative efficacy and adverse event profiles of these two widely used antipsychotics.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searched the Cochrane Schizophrenia Group's Register and other databases up to June 2004.
  • Extracted and analyzed dichotomous and continuous data using relative risks and weighted mean differences.

Related Experiment Videos

Main Results:

  • No significant difference in short-term outcomes (unchanged or worse symptoms).
  • Olanzapine showed a potential benefit in reducing relapse/rehospitalization at 12 months (NNT=7).
  • Both drugs had similar rates of adverse events, insomnia, and sleepiness; however, risperidone was associated with more extrapyramidal symptoms (NNH=8) and sexual dysfunction, while olanzapine caused significant weight gain (NNT=8).

Conclusions:

  • Risperidone and olanzapine exhibit comparable efficacy, with differences primarily in adverse effect profiles.
  • Risperidone is associated with movement disorders and sexual dysfunction, whereas olanzapine is linked to substantial weight gain.
  • Further large, independent pragmatic trials are needed to fully assess quality of life, service outcomes, and long-term effectiveness.